Bernard M Fine
Overview
Explore the profile of Bernard M Fine including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Ruijter L, van de Donk P, Hooiveld-Noeken J, Giesen D, Elias S, Lub-de Hooge M, et al.
Nat Med
. 2022 Dec;
28(12):2601-2610.
PMID: 36471036
Immune checkpoint inhibitors (ICIs), by reinvigorating CD8 T cell mediated immunity, have revolutionized cancer therapy. Yet, the systemic CD8 T cell distribution, a potential biomarker of ICI response, remains poorly...
2.
Li C, Zhang C, Li Z, Samineni D, Lu D, Wang B, et al.
MAbs
. 2019 Dec;
12(1):1699768.
PMID: 31852341
vc-MMAE antibody-drug conjugates (ADCs) consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a protease-labile valine-citrulline (vc) linker. The objective of this study was...
3.
Danila D, Szmulewitz R, Vaishampayan U, Higano C, Baron A, Gilbert H, et al.
J Clin Oncol
. 2019 Nov;
37(36):3518-3527.
PMID: 31689155
Purpose: Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) is highly expressed in prostate cancers. DSTP3086S is a humanized immunoglobulin G1 anti-STEAP1 monoclonal antibody linked to the potent antimitotic agent...
4.
Kagedal M, Samineni D, Gillespie W, Lu D, Fine B, Girish S, et al.
CPT Pharmacometrics Syst Pharmacol
. 2019 Jun;
8(8):606-615.
PMID: 31207190
Peripheral neuropathy (PN) is a common long-term debilitating toxicity of antimicrotubule agents. PN was the most frequent adverse event resulting in dose modifications and/or discontinuation of treatment for valine-citrulline-monomethylauristatin E...
5.
ODonoghue J, Danila D, Pandit-Taskar N, Beylergil V, Cheal S, Fleming S, et al.
Mol Pharm
. 2019 May;
16(7):3083-3090.
PMID: 31117485
A six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a newly identified target in prostate cancer. The use of radio-labeled STEAP1-targeting antibodies with positron emission tomography (PET) may allow for detection...
6.
Carrasquillo J, Fine B, Pandit-Taskar N, Larson S, Fleming S, Fox J, et al.
J Nucl Med
. 2019 May;
60(11):1517-1523.
PMID: 31053681
Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is a relatively newly identified target in prostate cancer. We evaluated the ability of PET/CT with Zr-DFO-MSTP2109A, an antibody that recognizes STEAP1, to detect...
7.
Bensch F, van der Veen E, Lub-de Hooge M, Jorritsma-Smit A, Boellaard R, Kok I, et al.
Nat Med
. 2018 Nov;
24(12):1852-1858.
PMID: 30478423
Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with...
8.
Kagedal M, Gibiansky L, Xu J, Wang X, Samineni D, Chen S, et al.
J Pharmacokinet Pharmacodyn
. 2017 Sep;
44(6):537-548.
PMID: 28918591
Antibody-drug conjugates (ADCs) developed using the valine-citrulline-MMAE (vc-MMAE) platform, consist of a monoclonal antibody (mAb) covalently bound with a potent anti-mitotic toxin (MMAE) through a protease-labile vc linker. Recently, clinical...
9.
Stagg N, Shen B, Brunstein F, Li C, Kamath A, Zhong F, et al.
Regul Toxicol Pharmacol
. 2016 Oct;
82:1-13.
PMID: 27773754
Antibody drug conjugates (ADC) consist of potent cytotoxic drugs conjugated to antibodies via chemical linkers, which enables specific targeting of tumor cells while reducing systemic exposure to the cytotoxic drug...
10.
Lamberts L, Menke-van der Houven van Oordt C, Ter Weele E, Bensch F, Smeenk M, Voortman J, et al.
Clin Cancer Res
. 2015 Nov;
22(7):1642-52.
PMID: 26589435
Purpose: Mesothelin (MSLN) is frequently overexpressed in pancreatic and ovarian cancers, making it a potential drug target. We performed an (89)Zr-PET imaging study with MMOT0530A, a MSLN antibody, in conjunction...